Take a trial of USA to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value

Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2008 2009 2010 2011 2012 2013 TTM 2014E 2015E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ -2.8%

FINANCIAL BRIEF: For the nine months ended 30 September 2014, Neuralstem, Inc. revenues decreased 87% to $14K. Net loss increased 4% to $17.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest expense increase of 27% to $1.2M (expense), Depreciation and amortization increase of 43% to $260K (expense), Other income decrease from $1K (income) to $0K. more »

Health Trend

Bankruptcy Risk

  Earnings Manipulation Risk

Magic Formula Score

Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %

Recent History
Latest interim period (ended 30th Sep '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2014
31st Dec 2015

Price Target: $7.00 (+145.61% above Price) Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a ($) ($) ($) ($) ($) ($)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Neuralstem Inc
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 1 2 0

Named Brokers and Analysts
H.C. Wainwright & Co., LLC , Morgan Joseph TriArtisan , Noble Financial Capital Markets Nathan Cali , Maxim Group Jason Kolbert , Zacks Investment , Aegis Capital Raghuram Selvaraju ,

Neuralstem, Inc. is a development-stage company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stems cells and the use of small molecule drugs. The Company has developed and maintains a portfolio of patents and patent applications that form base for its research and development efforts in the area of neural stem cell research. The Company's focus is the development of methods to generate replacement cells from neural stem cells. During the year ended December 31, 2011, the Company was selected as the primary subcontractor for the United States Department of Defense (DOD) contract to develop human neural stem cell technology for the treatment of cancerous brain tumors. The Company commenced work on the project in May 2011.

Directors: Karl Johe (CHM) 53, I. Richard Garr (PRE) 61, Sandford Smith (DRC) 67, Scott Ogilvie (IND) 58, William Oldaker (IND) 72, Catherine Sohn (IND) 61, Stanley Westreich (IND) 75,

No. of Employees: 15 No. of Shareholders: 414

Last Annual December 31st, 2013
Last Interim September 30th, 2014
Shares in Issue 87,359,665
Free Float 83.8m (95.9%)
Sector Healthcare
Industry Pharmaceuticals
Exchange NYSE MKT
Eligible for an ISA? a SIPP?

Address 9700 Great Seneca Highway, ROCKVILLE, 20850, United States
Web http://www.neuralstem.com
Phone +1 301 3664841
Contact David Castaneda (IR Contact)
Auditors Stegman & Company

CUR Share Price Performance CUR Quote
0.2  8.0%
Traded 9:03pm · Minimum 15 min delayed · NMS:

Latest CUR News Announcements (delayed)

Upcoming CUR Events
Monday 9th March, 2015 (estimate)
Q4 2014 Neuralstem Inc Earnings Release
Monday 22nd June, 2015 (estimate)
Neuralstem, Inc. Annual Shareholder Meeting

Recent ↓
Friday 7th November, 2014
Q3 2014 Neuralstem Inc Earnings Release
Friday 8th August, 2014
Q2 2014 Neuralstem Inc Earnings Release
Friday 27th June, 2014
Neuralstem, Inc. Annual Shareholder Meeting
Monday 12th May, 2014
Q1 2014 Neuralstem, Inc. Earnings Release
Tuesday 11th March, 2014
Neuralstem, Inc. at EBD BIO-Europe Spring
Monday 10th March, 2014
Q4 2013 Neuralstem, Inc. Earnings Release
Tuesday 11th February, 2014
Neuralstem, Inc. at Biotechnology Industry Organization CEO & Investor Conference
Tuesday 14th January, 2014
Neuralstem, Inc. at EBD Biotech Showcase
Tuesday 12th November, 2013
Q3 2013 Neuralstem, Inc. Earnings Release
Tuesday 10th September, 2013
Neuralstem, Inc. at Rodman & Renshaw Global Investment Conference

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.

Should you buy CUR

Access CUR Analytics Now!